Question · H1 2023
Qu Xiaoyi asked about the expected real-world prevalence of the patient population with high CD73 and PD-L1 expression for uliledlimab, and whether adding chemotherapy could improve response in patients with low PD-L1 expression.
Answer
CMO John Hayslip noted that since the trial enrolled patients regardless of CD73 status, the observed rates may be consistent with the real-world population. He and CEO Raj Kannan expressed optimism that combining uliledlimab with chemotherapy could broaden its benefit to more patients, potentially irrespective of their baseline CD73 or PD-L1 expression levels.